Objective:

To examine the demographic and clinical characteristics of patients receiving opioid agonist treatment (methadone or buprenorphine) compared to those taking prescription opioid analgesics at low (100 mg) doses.

Key Findings:

• Among 42,182 participants, 56.8% were female with a mean age of 51.7 years.
• Patients on opioid agonist treatment and high-dose opioids had more severe mental health symptoms and longer pain duration than those on low-dose opioids.
• Compared to the high-dose group, opioid agonist treatment patients reported lower pain intensity but higher rates of multimorbidity, severe anxiety, and pain catastrophizing.

Interpretation:

The findings emphasize the need for integrated mental health treatment and tailored multidisciplinary pain management for patients on opioid agonist treatment, highlighting the complexity of their clinical needs.

Limitations:

• Limited understanding of the unique clinical needs of patients on opioid agonist treatment, which may affect treatment outcomes.
• Potential biases in self-reported data and the cross-sectional nature of the study may limit the generalizability of the findings.

Conclusion:

The study highlights the complexity of managing pain in patients receiving opioid agonist treatment and underscores the necessity for comprehensive, multidisciplinary approaches tailored to their unique needs.